CytRx Corp. (CYTR) Continues to Build Oncology Portfolio, Headed by Lead Candidate Aldoxorubicin

CytRx is a biopharmaceutical research and development company with a particular focus on expanding its pipeline of oncology candidates in various stages of preclinical and clinical development.

Aldoxorubicin is the company’s novel version of the commonly prescribed chemotherapeutic agent doxorubicin, which is a standard chemotherapeutic treatment for a variety of cancers and is used either alone or in combination with other chemotherapy agents. Aldoxorubicin differs in that it has the potential to safely deliver greater amounts of doxorubicin directly to the tumor compared with standard doxorubicin treatment, which the company believes could lead to improved efficacy.

CytRx holds the exclusive worldwide rights to aldoxorubicin. The candidate has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with soft tissue sarcomas and pancreatic cancer.

CytRx recently announced favorable results from its phase 1b/2 clinical trial with aldoxorubicin in patients with advanced solid tumors, and has initiated a phase 2b international clinical trial in patients with soft tissue sarcomas, and a phase 2 clinical trial in patients with pancreatic cancer.

The company in December plans to report top-line phase 2b data, which the company anticipates will provide the first direct clinical trial comparison of aldoxorubicin with native doxorubicin as a first-line treatment for soft tissue sarcoma.

CytRx also has rights to two additional drug candidates: tamibarotene, for which the company has completed evaluation in the ENABLE Phase 2 clinical trial in lymphocytic leukemia and for which it plans to seek a partnership for further development; and befetinib, which the company is evaluating for further development.

For more information visit www.cytrx.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net